BurNIng

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

Retrieved on: 
Tuesday, April 12, 2022
Cream, Hormone, Pain, Progesterone, Woman, Menopause, COVID-19, NASDAQ, North American Menopause Society, Climacteric, Kuhl, GLOBE, Patient, VMS, Review, Trial of the century, Form, Sex, Forward-looking statement, Fracture, FDA, Quality of life, Health, Investor, PK, Bone loss, Sleep, Social media, Bacterial vaginosis, NAMS, Health minister, CEO, 8-K, Pharmacokinetics, Bone density, Twitter, The North American, Pharmacology, Intellectual property, Estradiol, Failure, Safety, HT, Personal lubricant, DOI, Hot flash, Birth, BurNIng, Fertility, SAN, Estrogen, Flash, IVR, Female, Harvard Medical School, Risk, Pharmaceutical industry, Birth control, Bayer

SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-HRT1.

Key Points: 
  • SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-HRT1.
  • Baseline-corrected steady state release level data from the prior Phase 1 study demonstrate that both dose versions of DARE-HRT1 successfully delivered two different bio-identical hormones over the 28-day evaluation period.
  • Dar Bioscience is a biopharmaceutical company committed to advancing innovative products for womens health.
  • Dar cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Galderma Launches TWYNEO® Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination to Treat Facial Acne

Retrieved on: 
Friday, March 25, 2022
Cream, Bajaj Consumer Care, Angioedema, Tanning, Hives, Association, Red, Exfoliation, Nasdaq, OTC, Acne, BurNIng, Facial, Pain, Abrasion, Dermatitis, View, Parent, Person, Stinger, Tretinoin, Erythema, Surge arrester, Anaphylaxis, Customer experience, Multimedia, AAD, Benzoyl peroxide, Press release, Sol–gel process, Irritation, American Academy of Dermatology, Physical, Pimple, American Academy, FDA, Patient, Partnership, FAAD, Marketing, Dry, Itch, British Journal of Dermatology, Skin, BPO, Epidemiology, Depression, Sunburn, Photosensitivity, Online shopping, Birth control, Sulfur, Cosmetics, MD, Dermatology, Galderma, Q2, Aesthetics

"TWYNEO Cream may help teens with acne especially the boys struggling with generic tretinoin or adhering to complex treatment routines, since it's a once-daily, potent combination that can be used any time of day."

Key Points: 
  • "TWYNEO Cream may help teens with acne especially the boys struggling with generic tretinoin or adhering to complex treatment routines, since it's a once-daily, potent combination that can be used any time of day."
  • A month's supply of TWYNEO Cream costs $0 for commercially covered patients or $60 for uninsured patients with the Galderma CAREConnect savings card.
  • TWYNEO Cream may cost less than generic tretinoin alone when using the Galderma CAREConnect savings card.
  • Indication:TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.

Galderma Launches TWYNEO® Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination to Treat Facial Acne

Retrieved on: 
Friday, March 25, 2022
Cream, Bajaj Consumer Care, Angioedema, Tanning, Hives, Association, Red, Exfoliation, Nasdaq, OTC, Acne, BurNIng, Facial, Pain, Abrasion, Dermatitis, Parent, Person, Stinger, Tretinoin, Erythema, Surge arrester, Anaphylaxis, Customer experience, AAD, Benzoyl peroxide, Press release, Sol–gel process, Irritation, American Academy of Dermatology, Physical, Pimple, American Academy, FDA, Patient, Partnership, FAAD, Marketing, Dry, Itch, British Journal of Dermatology, Skin, BPO, Epidemiology, Depression, Sunburn, Photosensitivity, Flour, Birth control, Sulfur, Cosmetics, MD, Dermatology, Galderma, Q2, Aesthetics

FORT WORTH, Texas, March 25, 2022 /PRNewswire/ -- Galderma announced today the U.S. launch of TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022, in Boston, Massachusetts. TWYNEO Cream is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne.1,2 Patented microencapsulation technology unites two ingredients that have not been previously combined and enables their controlled release to deliver visible results in as little as two weeks.2-4

Key Points: 
  • "TWYNEO Cream may help teens with acne especially the boys struggling with generic tretinoin or adhering to complex treatment routines, since it's a once-daily, potent combination that can be used any time of day."
  • A month's supply of TWYNEO Cream costs $0 for commercially covered patients or $60 for uninsured patients with the Galderma CAREConnect savings card.
  • TWYNEO Cream may cost less than generic tretinoin alone when using the Galderma CAREConnect savings card.
  • Indication:TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.

Developed by Practicing Podiatrist, Balance Doctor™ Introduces First Medical Sock that Looks and Feels Normal, Yet Designed to Soothe Chronic Neuropathic Pain Naturally - Balance Socks

Retrieved on: 
Tuesday, February 8, 2022
Pain, News, DPN, Science, Social media, Happiness, Renault Sport Series, Solution, Facebook, Twitter, Proprioception, Ankle, Quality of life, Sport, Exercise, Patient, Stabbing, Achilles tendon, PN, Brain, Balance, Achilles, BurNIng, Chronic pain, Instagram, Neuropathic pain, LinkedIn, Peripheral neuropathy, Dietary supplement, Pharmaceutical industry

Balance Sock's special design also provides an optimal amount of strategic Achilles cushioning, activating the body's natural feedback/balance system.

Key Points: 
  • Balance Sock's special design also provides an optimal amount of strategic Achilles cushioning, activating the body's natural feedback/balance system.
  • Early clinical trials indicate that Balance Socks can help people achieve up to 24% better balance and significantly reduce pain in over 90% of patients.
  • For more information on Balance Socks, the science of NeuroBalance and the Neurotech Band, visit Balance Doctor online.
  • Based in Alabama with products manufactured in Tennessee, Balance Doctor provides a wide range of socks engineered to help people suffering with neuropathic foot pain, circulation, and balance issues.

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

Retrieved on: 
Monday, December 6, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Optical, Other Science, Research, Science, Clinical Trials, Patient, Gauge (instrument), VAS, Irritation, Cataract, Red, Axitinib, Safety, IOP, International, Toxic epidermal necrolysis, Private Securities Litigation Reform Act, Company, Duane syndrome, Population, Retina, Compliance, Arthralgia, MD, MCMC, Dry eye syndrome, MBA, Clinical trial, Inflammation, FCS, U.S. Securities and Exchange Commission, Eye, COVID-19, Program, Pain, Tears, AMD, Stinger, Ocular hypertension, BurNIng, FDA, ITT, Webcast, Intraocular pressure, Dexamethasone, Observation, Method, Allergic conjunctivitis, NASDAQ, Lists of diseases, Security (finance), Pharmaceutical industry, Telescopic sight, Dry Eye Disease, Ocular Therapeutix, Inc., DRY EYE DISEASE, OCULAR THERAPEUTIX, INC.

The Phase 2 clinical trial is a U.S.-based, randomized, double-masked, vehicle-controlled, multi-center trial evaluating two different formulations of OTX-DED (dexamethasone intracanalicular ophthalmic insert) aimed to enroll approximately 150 subjects with dry eye disease.

Key Points: 
  • The Phase 2 clinical trial is a U.S.-based, randomized, double-masked, vehicle-controlled, multi-center trial evaluating two different formulations of OTX-DED (dexamethasone intracanalicular ophthalmic insert) aimed to enroll approximately 150 subjects with dry eye disease.
  • In my clinical experience, many dry eye patients experience episodic flares of their signs and symptoms related primarily to inflammation.
  • ET to discuss the topline results for the Phase 2 clinical trial of OTX-DED for the short-term treatment of dry eye disease.
  • Ocular Therapeutix is currently evaluating OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials.

FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis

Retrieved on: 
Tuesday, September 21, 2021
Tablet, Food, Therapy, Miliaria, Rosacea, Irritation, Steroid, Hyperglycemia, Prevalence, BurNIng, Compliance, Itch, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Torso, FDA, Patient, Adolescence, Folliculitis, Body surface area, Scalp, Adult, Allergic contact dermatitis, Doxycycline, Immune system, Hypopigmentation, Glycosuria, Phase, CEO, Telangiectasia, Company, Ageing, Acne, Greasy hair, Dry, Hospira, ASX, Risk, Cushing's syndrome, Perioral dermatitis, Dermatology, Atrophy, Cell, Safety, Infection, Glaucoma, National Psoriasis Foundation, Ulobetasol, HPA, Time, Skin, Pharmaceutical industry, Cosmetics, Generic drug

LEXETTE, a super potent topical corticosteroid,is now approved for the treatment of plaque psoriasis in patients aged 12 years and older.

Key Points: 
  • LEXETTE, a super potent topical corticosteroid,is now approved for the treatment of plaque psoriasis in patients aged 12 years and older.
  • The FDA approved LEXETTE in 2018 based on evidence from two multicentre, randomized, double-blind, vehicle-controlled studies (n=560) in patients with plaque psoriasis involving between 2% to 12% body surface area.
  • LEXETTE (halobetasol propionate) foam is a potent corticosteroid indicated for the topical treatment of plaque psoriasis in patients twelve years of age and older.
  • LEXETTE foam was evaluated for the treatment of moderate to severe plaque psoriasis in two multicentre, randomised, double-blind, vehicle-controlled studies.